Two New Drugs of National Category 1.1 Got Clinical Acceptance Notification


In May 2014, the clinical trial application of ProteLight’s two national category 1.1 new drugs, antimicrobial peptide PL-5 active pharmaceutical ingredient and its preparation accepted by Jilin FDA, and we got the notification of application acceptance for drug registration, that means the two drugs were in the process of registration application.


Antimicrobial peptide PL-5 has clear intellectual property right protection, and is applicable to most of skin infections (including stubborn infectious disease initiated by drug resistant bacteria, such as diabetic foot and bed sore),. It is defined as a project of “12th five-year plan” key innovative new drug manufacture projects in 2012 and got support as“Science and Technology Innovation Fund (growth type)” project of Ministry of Science and Tehcnology.